1SACCO R L,BENJAMIN E J,BRODERICK J P,et al. Risk factors AHA Conference Proceedings [ J ]. Stroke, 1997,28 ( 8 ) : 1507 - 1517.
2KUO K,STILL R,CALE S,et al. Standardization (external and internal) of HPLC assay for plasma homocysteine[ J ]. Clin Chem, 1997,43(9) : 1653 - 1655.
3KANG S S. Treatment of hyperhomoeyst (e)inemia: physiological basis[J]. Nutr,1996,126(4 Suppl) :1273 - 1275..
4PERRY I J,REFSUM H,MORRIS R W,et al. Prospective study of serum total concentration and risk of stroke in middle - aged British men [ J ]. Lancet, 1995,346 ( 8987 ) : 1396 - 1398.
7STEHOUWER C D,WEIJENBERG M P,VANDEN B M,et al. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men:a 10 -year follow- up. J. ArteriosclerThromb Vasc Biol,1998,18(12) :1895 -1901.
8GRAEME J, HANKEY M D, FRCP, FRACP ; John W. Eikelboom, MBBS, MSc, FRACP, FRCPA Folic Acid- Based Multivitamin Therapy to Prevent Stroke[ J]. Stroke,2004,35 (5) : 1995 - 1998.
10Stam ler J S, O shome J A, Jaraki O, et al. Adverse vascular ef-fects of hom ocysteine are modu lated by endo thelium-derived re-laxing factor and related oxides of nitrogen[J]. chin Invest,1993,91:308-313.
